Implementation of mechanism of action biology-driven early drug development for children with cancer
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
Grant support
15958
Cancer Research UK - United Kingdom
18339
Cancer Research UK - United Kingdom
PubMed
27258969
DOI
10.1016/j.ejca.2016.04.001
PII: S0959-8049(16)32059-7
Knihovny.cz E-resources
- Keywords
- Mechanism of action, Paediatric oncology, Targeted cancer drug development,
- MeSH
- Molecular Targeted Therapy methods MeSH
- Databases, Factual MeSH
- Child MeSH
- Drug Industry methods MeSH
- Drug Evaluation MeSH
- Medical Oncology methods MeSH
- Humans MeSH
- Neoplasms drug therapy MeSH
- Drug Discovery methods MeSH
- Antineoplastic Agents therapeutic use MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antineoplastic Agents MeSH
An urgent need remains for new paediatric oncology drugs to cure children who die from cancer and to reduce drug-related sequelae in survivors. In 2007, the European Paediatric Regulation came into law requiring industry to create paediatric drug (all types of medicinal products) development programmes alongside those for adults. Unfortunately, paediatric drug development is still largely centred on adult conditions and not a mechanism of action (MoA)-based model, even though this would be more logical for childhood tumours as these have much fewer non-synonymous coding mutations than adult malignancies. Recent large-scale sequencing by International Genome Consortium and Paediatric Cancer Genome Project has further shown that the genetic and epigenetic repertoire of driver mutations in specific childhood malignancies differs from more common adult-type malignancies. To bring about much needed change, a Paediatric Platform, ACCELERATE, was proposed in 2013 by the Cancer Drug Development Forum, Innovative Therapies for Children with Cancer, the European Network for Cancer Research in Children and Adolescents and the European Society for Paediatric Oncology. The Platform, comprising multiple stakeholders in paediatric oncology, has three working groups, one with responsibility for promoting and developing high-quality MoA-informed paediatric drug development programmes, including specific measures for adolescents. Key is the establishment of a freely accessible aggregated database of paediatric biological tumour drug targets to be aligned with an aggregated pipeline of drugs. This will enable prioritisation and conduct of early phase clinical paediatric trials to evaluate these drugs against promising therapeutic targets and to generate clinical paediatric efficacy and safety data in an accelerated time frame. Through this work, the Platform seeks to ensure that potentially effective drugs, where the MoA is known and thought to be relevant to paediatric malignancies, are evaluated in early phase clinical trials, and that this approach to generate pre-clinical and clinical data is systematically pursued by academia, sponsors, industry, and regulatory bodies to bring new paediatric oncology drugs to front-line therapy more rapidly.
Belgian Federal Agency for Medicines and Health Products Brussels Belgium
Bristol Myers Squibb 5 Research Parkway Wallingford CT 06492 USA
Centre for English Language Teaching University of York UK
Clinical Cooperation Unit Pediatric Oncology Heidelberg Germany
Create for Chloe and UK representative for aPODD UK
Department of Clinical Research Institut Gustave Roussy Paris Sud University Paris France
Department of Pediatric and Adolescent Oncology Gustave Roussy France
Division of Clinical Studies The Institute of Cancer Research London UK
Genentech Inc 1 DNA Way South San Francisco CA 94080 USA
German Cancer Research Center and Heidelberg University Hospital Heidelberg 69120 Germany
Novartis Pharma AG Basel CH 4002 Switzerland
Paediatric Haematology Oncology Unit Antwerp University Hospital Antwerp University Belgium
Product Development Scientific Support Department European Medicines Agency Canary Wharf London UK
TetraLogic Pharmaceuticals Malvern PA 19355 USA
The Institute of Cancer Research The Royal Marsden NHS Foundation Trust Sutton London UK
References provided by Crossref.org
